ClinicalTrials.gg
WithdrawnNCT02568111BRITEUpdated Apr 25, 2016

Brimonidine Tartrate for the Treatment of Injection Related Erythema

A Phase 4 interventional study of peginterferon beta-1a and brimonidine tartrate in Relapsing-Remitting Multiple Sclerosis (RRMS), sponsored by Biogen. Withdrawn. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-04-25.

Sponsored by Biogen · Phase 4, Interventional, and Supportive care

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 78 studies in Multiple Sclerosis, Relapsing-Remitting by Biogen — none open to participants now, 1 under way, 1 of them phase 3. Multiple Sclerosis, Relapsing-Remitting · Biogen.

Enrollment
55th of 59
0 · median 152
Started
2016
with 3 others
Phase 4
21 of 78
none open now
Registered
58th of 78
by date

Among the 78 studies in Multiple Sclerosis, Relapsing-Remitting by Biogen, this one is the 55th largest by enrollment of the 59 interventional ones that give a count, is one of 4 that started in 2016, is one of 21 in phase 4, and was the 58th registered.

Multiple Sclerosis, Relapsing-Remitting

618 studies on the registry are indexed under Multiple Sclerosis, Relapsing-Remitting; 83 are open to participants now.

Browse Multiple Sclerosis, Relapsing-Remitting studies →

Open to participants now

None of the 78 studies in Multiple Sclerosis, Relapsing-Remitting by Biogen is open now. The open studies under Multiple Sclerosis, Relapsing-Remitting, anywhere →

Who these studies take

Of the 60 Multiple Sclerosis, Relapsing-Remitting studies recruiting now, 11 (18%) set no upper age limit and 43 (72%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 78 studies in Multiple Sclerosis, Relapsing-Remitting by Biogen as a file.
02

Study summary

The primary objective of this study is to evaluate the Injection Related Erythema (IRE) mitigation effect of a single administration of brimonidine tartrate in comparison with a vehicle gel (placebo).

The secondary study objectives are to evaluate the IRE mitigation effect of a single administration of brimonidine tartrate in comparison with a vehicle gel on a more stringent definition scale, in accordance with the primary endpoint of the original brimonidine pivotal trials and participants' satisfaction with the overall appearance of their skin.

Read the detailed description

Participants naïve to treatment with subcutaneous (SC) interferons or oral Disease Modifying Therapy (DMT) who are about to start PLEGRIDY PEN therapy will be screened for participation in this Phase IV trial. Participants will remain on Plegridy therapy as prescribed by their physician. Plegridy will not be provided to participants by Biogen as a part of this study.

03

Conditions studied

  • Relapsing-Remitting Multiple Sclerosis (RRMS)

Keywords

  • erythema
  • PLEGRIDY
  • injection site reaction (ISR)
  • MS
  • RRMS
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • RRMS patients naïve to treatment with SC interferon or oral and/or IV DMT for which PLEGRIDY is deemed necessary by the treating physician.
  • Patient willing and able to complete PSA and PAA questionnaires with minimal assistance.

Key Exclusion Criteria:

  • Known allergy to any interferon or any component of peginterferon beta-1a.
  • Patients with to Brimonidine topical gel.
  • Patients with other skin disorders.
  • History of previous treatment with Brimonidine tartrate.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    brimonidine tartrate

    Participants will apply gel to injection site erythema area after IRE development post peginterferon beta-1a injection

    Drug: peginterferon beta-1a · Drug: brimonidine tartrate

  • Placebo comparator
    Vehicle Gel

    Participants will apply vehicle gel placebo to injection site erythema area after IRE development post peginterferon beta-1a injection

    Drug: peginterferon beta-1a · Drug: Vehicle Gel

Interventions

  • SC administration as prescribed by the physician- initial dose of 63 μg followed by 94 μg dose on day 15 and 125 μg on day 29

    Also known as: PEGylated Interferon Beta-1a, PEG IFN β-1a, Plegridy, BIIB017

  • Applied to injection site as specified in the treatment arm. Commercially available Mirvaso (Brimonidine tartrate) gel will be provided by Galderma.

    Also known as: Mirvaso

  • DrugVehicle Gel

    Matched placebo applied to injection site as specified in the treatment arm. Matching vehicle gel will be provided by Galderma.

06

What researchers measure

Primary outcomes

  1. Change in either Clinician's Erythema Assessment (CEA) or Patient Erythema Self-Assessment (PSA) scale measured as at least 1-grade improvement on CEA and/or at least 1-grade improvement on PSA scale assessed by the physician and participant

    Investigator will evaluate participant's erythema (redness) at the site of injection on a scale of 0 (clear) to 4 (severe) with higher scores indicating higher levels of erythema. Participants rate erythema at the site of injection on a scale of 0 (clear) to 4 (severe) with higher scores indicating higher levels of erythema.

    Time frame: Before and after 6 hours of gel application

Secondary outcomes

  1. Composite change in both CEA and PSA scale measured as at least 1-grade improvement on CEA and 1-grade improvement on PSA respectively

    This composite endpoint is considered to be sensitive enough and directly correlated with participants' satisfaction therapy outcomes.

    Time frame: Before and after 6 hours of gel application

  2. Composite change in both CEA and PSA scale measured as at least 2-grade improvement on CEA and 2-grade improvement on PSA

    Time frame: Before and after 6 hours of gel application

  3. Participant's self-assessment of satisfaction with the overall appearance of their skin by using a Patient's Assessment of Appearance (PAA) grading scale

    PAA satisfaction score will describe how satisfied the participants are with the overall appearance of skin on a scale of 0 (very satisfied) to 4 (very dissatisfied).

    Time frame: Before and after 6 hours of gel application

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2016, a primary completion of Aug 2016 and a completion of Aug 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 1, 2015
First posted
Oct 5, 2015
Start
Feb 2016
Primary completionEst.
Aug 2016
CompletionEst.
Aug 2016
Last update
Apr 25, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 25, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02568111
Lead sponsor
Biogen
Responsible party
Sponsor
First posted
Oct 5, 2015
Start date
Feb 2016
Primary completion
Aug 2016 (estimated)
Completion
Aug 2016 (estimated)
Last update
Apr 25, 2016

Study contacts

Medical Director
study director · Biogen
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Apr 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brimonidine

Start the discussion